Researchers track Long-Term survival after new stomach cancer drug
NCT ID NCT07547787
First seen Apr 25, 2026 · Last updated May 19, 2026 · Updated 3 times
Summary
This study is for people with advanced stomach cancer who have already been treated with the drug cadonilimab in a previous clinical trial. The goal is to collect long-term information, such as how long patients live, to better understand the drug's lasting effects. No new treatments are given—this is an observational follow-up only.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.